AU2001237215A1 - Genetically modified fibroblast cell - Google Patents

Genetically modified fibroblast cell

Info

Publication number
AU2001237215A1
AU2001237215A1 AU2001237215A AU3721501A AU2001237215A1 AU 2001237215 A1 AU2001237215 A1 AU 2001237215A1 AU 2001237215 A AU2001237215 A AU 2001237215A AU 3721501 A AU3721501 A AU 3721501A AU 2001237215 A1 AU2001237215 A1 AU 2001237215A1
Authority
AU
Australia
Prior art keywords
genetically modified
fibroblast cell
modified fibroblast
cell
genetically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001237215A
Other languages
English (en)
Inventor
Sven Andrecht
Peter Angel
Norbert Fusenig
Andrea Kolbus
Nicole Maas-Szabowski
Marina Schorpp-Kistner
Axel Szabowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of AU2001237215A1 publication Critical patent/AU2001237215A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001237215A 2000-01-14 2001-01-12 Genetically modified fibroblast cell Abandoned AU2001237215A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10011926A DE10011926A1 (de) 2000-01-14 2000-01-14 Genetisch veränderte Fibroblastenzellen
DE10011926 2000-01-14
PCT/DE2001/000131 WO2001051619A2 (de) 2000-01-14 2001-01-12 Genetisch veränderte fibroblastenzellen

Publications (1)

Publication Number Publication Date
AU2001237215A1 true AU2001237215A1 (en) 2001-07-24

Family

ID=7634370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001237215A Abandoned AU2001237215A1 (en) 2000-01-14 2001-01-12 Genetically modified fibroblast cell

Country Status (7)

Country Link
US (1) US6846674B2 (de)
EP (1) EP1248835A2 (de)
JP (1) JP2003519487A (de)
AU (1) AU2001237215A1 (de)
CA (1) CA2396996A1 (de)
DE (1) DE10011926A1 (de)
WO (1) WO2001051619A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482030A1 (de) * 2003-05-28 2004-12-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Methode zur Erhöhung des Ertrags an proliferierenden primären Keratinozyten
EP1557085A1 (de) * 2004-01-21 2005-07-27 Boehringer Ingelheim International GmbH Mausmodell für menschliche Psoriasis
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
JP2017112998A (ja) * 2015-12-18 2017-06-29 富士フイルム株式会社 細胞積層体、生体移植材料、表皮の分化状態の評価方法及び細胞積層体の製造方法、並びにインスリン様成長因子−１産生促進剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1055366A1 (de) * 1999-05-26 2000-11-29 Boehringer Ingelheim International GmbH Verwendung von transgenen mäusen mit fehlender expression von jun-b in myeloidzellen

Also Published As

Publication number Publication date
EP1248835A2 (de) 2002-10-16
US20030109474A1 (en) 2003-06-12
WO2001051619A3 (de) 2002-02-14
DE10011926A1 (de) 2001-08-02
US6846674B2 (en) 2005-01-25
JP2003519487A (ja) 2003-06-24
WO2001051619A2 (de) 2001-07-19
CA2396996A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
AU2001252014A1 (en) Photovoltaic cell
AU2002368042A1 (en) Photovoltaic cell
AU4848800A (en) Selectively arrangeable pallet
AU6864600A (en) Fuel cell
AU5805700A (en) Glucoamylase variant
AU5268001A (en) Fuel cell
AU7098000A (en) Signed group criteria
GB9904905D0 (en) Cells
AU2001267078A1 (en) Alkaline cell
AU6955100A (en) Battery
AU2001292317A1 (en) Fuel cell
AU2001252015A1 (en) Photovoltaic cell
AU5043600A (en) Battery
AU2035601A (en) Load cell
AU1106401A (en) Battery
AU5171600A (en) Battery
AU5691800A (en) Structure
AU2001293074A1 (en) Human liver cell line
AU5061000A (en) Novel glucoamylase
AU2001267076A1 (en) Alkaline cell
AU2001267724A1 (en) Electrochemical cell
AU6179400A (en) Multi-photodetector unit cell
AU4391900A (en) Electrochemical cell
AU2201501A (en) Structure
AU2001269081A1 (en) Electrochemical cells

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 16, NO 5, PAGE(S) 912-919 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 21850/01, 22313/01, 23941/01, 26821/01, 29958/01, 29960/01, 29962/01, 29964/01, 37215/01, 39130/01 AND 90162/01